NICE – National Institute for Health and Care Excellence
Manchester, United Kingdom
NICE’s role is to improve outcomes for people using the NHS and other public health and social care services. We do this by:
- Producing evidence-based guidance and advice for health, public health and social care practitioners.
- Developing quality standards and performance metrics for those providing and commissioning health, public health and social care services.
- Providing a range of information services for commissioners, practitioners and managers across the spectrum of health and social care.
History & structure
NICE was set up in 1999 as the National Institute for Clinical Excellence to reduce variation in the availability and quality of NHS treatments and care. In 2005 we merged with the Health Development Agency, and began developing public health guidance, also changing our name (National Institute for Health and Clinical Excellence).
The Health and Social Care Act 2012 established us in primary legislation and from April 2013 we became a Non-Departmental Public Body responsible for developing guidance and quality standards in social care. Our name changed once more to reflect these new responsibilities.
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care.
How the agency works
NICE is led by a Board comprised of a non-executive chair and non-executive directors who in turn appoint executive members of the board. The NICE Board sets our strategic priorities and policies, with operational decision-making by our Senior Management Team.
All NICE guidance and other outputs, including the evidence or HTA reports on which they are based, are available on our website. Reuse of NICE guidance and corporate documents is covered by a licensing framework dependent on where our content is to be used. In the UK it may be used free of charge, under the NICE UK Open Content Licence. Outside the UK it may be used for personal education purposes, or else is subject to a licensing agreement.
A list of recently completed or milestone HTA reports
Details of published HTA topics are available on the NICE website.
A list of (selected) current projects
At any one time, NICE has approximately 500 guidance topics in development or at public consultation. Details, including expected publication dates, are available on NICE the website.
The future plan can be found in the NICE business plan. This plan sets out our business objectives and performance measures for 2019/20.
Country: The way NICE was established in legislation means our guidance applies in England only. However, we have agreements to provide certain NICE products and services to Wales, Scotland and Northern Ireland. Decisions on how our guidance applies in these countries are made by the devolved administrations, who are involved in the development of NICE guidance.
Description of population served (national, regional, etc.): National
Size of population served (mil): England – 55 million. Total UK population: 65 million.
Current HTA budget (mil USD): 2019/20 budget is GBP 68.2m (approximately USD 90m)
Permanent staff: NICE has 680 employees, many qualified to fulfil analytical and advice roles across a spectrum of clinical, public health and social care settings, along with operational support to manage the advisory committees who help us produce evidence-based guidance and appraisals.
Main bodies providing HTA services to NICE: Newcastle upon Tyne Hospitals NHS Foundation Trust external assessment centre; BMJ Technology Assessment Group (BMJ-TAG); Kleijnen Reviews Ltd (KSR); Centre for Reviews and Dissemination and Centre for Health Economics – York; Peninsula Technology Assessment Group (PenTAG); Southampton Health Technology Assessment Centre (SHTAC); Warwick Evidence; Liverpool Reviews and Implementation Group (LRiG); Aberdeen HTA Group; School of Health and Related Research (ScHARR); Decision Support Unit (DSU).
Ongoing TA projects: At any one time, NICE has approximately 500 guidance topics in development or at public consultation.
Director: Sir Andrew Dillon, Chief Executive
Contact person: Mirella Marlow, Programme Director
Level 1A, City Tower
M1 4BT, United Kingdom